Legend Biotech : Voting Results of 2023 Annual General Meeting - Form 6-K
September 25, 2023 at 08:03 am
Share
Voting Results of 2023 Annual General Meeting
At Legend Biotech Corporation's (the "Company") annual general meeting of shareholders held on September 21, 2023 (the "AGM"), the Company's shareholders:
•
received the audited consolidated financial statements of the Company for the fiscal year ended December 31, 2022;
•
ratified the appointment of Ernst & Young LLP as the Company's independent auditor for the fiscal year ending December 31, 2023;
•
re-elected each of Dr. Li Zhu, Dr. Corazon D. Sanders, and Dr. Li Mao to serve as a Class III director for a three-year term; and
•
authorized each of the directors and officers of the Company to take any and every action that might be necessary to effect the forgoing resolutions as such director or officer, in his or her absolute discretion, thinks fit.
A total of approximately 362,167,226 ordinary shares, including those underlying ADSs, representing approximately 99.34% of the ordinary shares issued and outstanding as of August 18, 2023, the record date, were present in person or by proxy at the AGM. The results of the votes are as follows:
For
Against
Abstain
Resolutions
Votes
%
Votes
%
Votes
%
Reception of Audited Financial Statements
362,063,064
99.310
%
732
*
%
103,430
0.028
%
Ratification of appointment of Ernst & Young LLP as Independent Auditor for Fiscal Year 2023
361,846,756
99.251
%
283,018
0.078
%
37,452
0.010
%
Election of Directors
Dr. Li Zhu (Class III)
360,542,838
98.894
%
1,593,518
0.437
%
30,870
0.008
%
Dr. Corazon D. Sanders (Class III)
352,917,796
96.802
%
9,218,874
2.529
%
30,556
0.008
%
Dr. Li Mao
(Class III)
359,725,136
98.669
%
2,410,190
0.661
%
31,900
0.009
%
Authorization of Directors and Officers
362,126,314
99.328
%
11,696
0.003
%
29,216
0.008
%
*
Less than 0.001%
Dr. Fangliang Zhang, Chairman of the Board of Directors, as the person designated by the Company, was granted a discretionary proxy by JPMorgan Chase Bank, N.A., the depositary of the ADSs, pursuant to the Deposit Agreement governing the ADSs and the Voting Instruction Card mailed by the depositary to the holders of the ADSs, to vote 11,912,282 ordinary shares underlying ADSs for which no voting instructions were given by the holders, and he exercised the discretionary proxy to vote in favor of each of the proposals submitted for shareholder approval at the AGM.
Legend Biotech Corporation published this content on 25 September 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 September 2023 12:02:03 UTC.
Legend Biotech Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.